CA3104833A1 - A combination product for use in tumor vaccination. - Google Patents

A combination product for use in tumor vaccination. Download PDF

Info

Publication number
CA3104833A1
CA3104833A1 CA3104833A CA3104833A CA3104833A1 CA 3104833 A1 CA3104833 A1 CA 3104833A1 CA 3104833 A CA3104833 A CA 3104833A CA 3104833 A CA3104833 A CA 3104833A CA 3104833 A1 CA3104833 A1 CA 3104833A1
Authority
CA
Canada
Prior art keywords
polypeptide
tumor
nucleic acid
acid encoding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104833A
Other languages
English (en)
French (fr)
Inventor
Erik Hans MANTING
Satwinder Kaur SINGH
Adriana Maria KRUISBEEK
Vinod SOMMANDAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus BV
Original Assignee
DCPrime BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DCPrime BV filed Critical DCPrime BV
Publication of CA3104833A1 publication Critical patent/CA3104833A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3104833A 2018-07-16 2019-07-16 A combination product for use in tumor vaccination. Pending CA3104833A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18183694 2018-07-16
EP18183694.1 2018-07-16
EP19170999.7 2019-04-25
EP19170999 2019-04-25
PCT/NL2019/050451 WO2020017962A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.

Publications (1)

Publication Number Publication Date
CA3104833A1 true CA3104833A1 (en) 2020-01-23

Family

ID=67544309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104833A Pending CA3104833A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.

Country Status (5)

Country Link
US (2) US11071778B2 (https=)
EP (1) EP3823668A1 (https=)
JP (1) JP2021531345A (https=)
CA (1) CA3104833A1 (https=)
WO (1) WO2020017962A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191871A1 (en) * 2020-03-27 2021-09-30 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12364758B2 (en) 2020-06-30 2025-07-22 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
US12397055B2 (en) 2021-01-22 2025-08-26 Mendus B.V. Methods of tumor vaccination

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020524710A (ja) 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
AU2019414934A1 (en) 2018-12-27 2021-06-24 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CA3133410A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
CA3195963A1 (en) 2020-10-19 2022-04-28 Joshua Weiyuan WANG Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
CA3196677A1 (en) * 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
WO2024197451A1 (en) * 2023-03-24 2024-10-03 Virogin Biotech (Shanghai) Ltd. Homologous and heterologous therapeutic vaccination strategies for cancer treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
WO2001049317A2 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
PT1346059E (pt) 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
AU2006260240B2 (en) 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009127988A1 (en) 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009019320A2 (en) 2008-05-19 2009-02-12 Dcprime B.V. Method for inducing and accelerating cells
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
CN103179952B (zh) 2010-09-02 2015-06-03 斯克里普斯研究学院 基于纳米颗粒的肿瘤靶向药物递送
GB201106357D0 (en) * 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
GB201519303D0 (en) * 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
BR112019001115A2 (pt) * 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191871A1 (en) * 2020-03-27 2021-09-30 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12364758B2 (en) 2020-06-30 2025-07-22 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
US12397055B2 (en) 2021-01-22 2025-08-26 Mendus B.V. Methods of tumor vaccination

Also Published As

Publication number Publication date
US11071778B2 (en) 2021-07-27
JP2021531345A (ja) 2021-11-18
WO2020017962A1 (en) 2020-01-23
US20220023406A1 (en) 2022-01-27
US20200397883A1 (en) 2020-12-24
EP3823668A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
US11071778B2 (en) Combination product for use in tumor vaccination
US11052144B2 (en) Methods of tumor vaccination
KR101650364B1 (ko) 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질
US9962436B2 (en) Multimeric fusion protein vaccine and immunotherapeutic
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
JP2017509652A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
US20210009716A1 (en) Synthetic proteins and therapeutic uses thereof
EP4408461A1 (en) Methods and particles for modulating an immune response
JP2025526447A (ja) 抗原送達用組換え融合タンパク質およびその使用
KR20230008162A (ko) 암 및 감염성 질환에 대한 면역요법을 위한 융합 단백질
TWI881028B (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
Johansson et al. Intracellular targeting of CEA results in Th1‐type antibody responses following intradermal genetic vaccination by a needle‐free jet injection device
CN114269792B (zh) 稳定的嵌合合成蛋白及其治疗用途
WO2025246436A1 (en) Circular rna-based therapeutic vaccine for treating hpv positive cancer
US20250101128A1 (en) Chimeric polypeptide compositions and encoding polynucleotides thereof
Joe Enhancing the immunogenicity and functionality of hepatitis B surface antigen virus-like particles
WO2024049990A1 (en) Nanoparticle-derived vaccines against poxviruses, and methods for making and using the same
CN121518519A (zh) 多价猪圆环病毒疫苗
김형윤 Development of Human Papillomavirus (HPV) Vaccine Using Human Cysteinyl-tRNA Synthetase 1 and Tumor Antigens
WO2003050268A2 (en) Enhancement of the immune response using cd36-binding domain
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916